Eric I. Marks, MD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Pennsylvania State College of Medicine

Dr. Eric Marks is an Assistant Professor of Medicine at Boston University School of Medicine. He currently specializes in gastrointestinal oncology and sarcomas. Dr. Marks graduated from the University of Massachusetts and subsequently pursued medical school and a residency in Internal Medicine at Pennsylvania State University. He then completed his fellowship in hematology and medical oncology at the Warren Alpert Medical School of Brown University, where he published several studies focused on gastrointestinal malignancies.

2019 Brown University: Certificate of exemplary teaching
2016 Penn State Cancer Institute house-staff award for clinical performance

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. Am J Clin Oncol. 2021 02 01; 44(2):68-73. PMID: 33298767
  2. Marks EI, Brown VS, Dizon DS. Am J Clin Oncol. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma. 2020; 43(2):139-145.
  3. Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro B. ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. Oncotarget. 2019; 10:245-251.
  4. Marks EI, Ollila TA. Acanthocytosis causing chronic hemolysis in a patient with advanced cirrhosis. Blood. 2019; 133:1518.
  5. Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhairu V, Marks E, Richardson AE, Krecko L, Ali A, Koestler W, Esteva FJ, Leeming DJ, Karsdal MA, Willumsen N. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 2018 12 01; 143(11):3027-3034. PMID: 29923614; DOI: 10.1002/ijc.31627;
  6. Yacur M, Marks EI, Suleski J, Joshi M. Expression of Beta-Human Chorionic Gonadotropin (BetaHCG) in Transitional Cell Carcinoma. Annals of Carcinogenesis. 2017; 2(2):1012-1016.
  7. Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol. 2016 Jan 28; 22(4):1335-47. PMID: 26819503; PMCID: PMC4721969; DOI: 10.3748/wjg.v22.i4.1335;
  8. Marks EI, Yee NS. World J of Gastroenterol. Molecular genetics and targeted therapeutics in biliary tract carcinoma. 2016; 22(4):1335-1347.
  9. Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J Gastrointest Oncol. 2015 Nov 15; 7(11):338-46. PMID: 26600933; PMCID: PMC4644856; DOI: 10.4251/wjgo.v7.i11.338;
  10. Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015; 16(12):1710-9. PMID: 26561209; PMCID: PMC4847811; DOI: 10.1080/15384047.2015.1113355;
Showing 10 of 15 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 15 publications over 7 distinct years, with a maximum of 7 publications in 2015


Contact for Mentoring:
Marks's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department